| Literature DB >> 27791341 |
Paul A Bruno1,2, Alex Morriss-Andrews1, Andrew R Henderson1,2, Charles L Brooks1, Anna K Mapp1,2.
Abstract
Aberrant canonical NF-κB signaling is implicated in diseases from autoimmune disorders to cancer. A major therapeutic challenge is the need for selective inhibition of the canonical pathway without impacting the many non-canonical NF-κB functions. Here we show that a selective peptide-based inhibitor of canonical NF-κB signaling, in which a hydrogen bond in the NBD peptide is synthetically replaced by a non-labile bond, shows an about 10-fold increased potency relative to the original inhibitor. Not only is this molecule, NBD2, a powerful tool for dissection of canonical NF-κB signaling in disease models and healthy tissues, the success of the synthetic loop replacement suggests that the general strategy could be useful for discovering modulators of the many protein-protein interactions mediated by such structures.Entities:
Keywords: inhibitors; medical chemistry; peptide loops; peptidomimetics; protein-protein interactions
Mesh:
Substances:
Year: 2016 PMID: 27791341 PMCID: PMC5587901 DOI: 10.1002/anie.201607990
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336